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Abstract— There is a growing body of applications leveraging 
Microsoft Kinect and the associated Windows Software 
Development Kit in health and wellness.  In particular, this 
platform has been valuable in developing interactive solutions for 
rehabilitation including creating more engaging exercise 
regimens and ensuring that exercises are performed correctly for 
optimal outcomes.  
Clinical trials rely upon robust and validated methodologies 
to measure health status and to detect treatment-related changes 
over time to enable the efficacy and safety of new drug 
treatments to be assessed and measured.  In many therapeutic 
areas, traditional outcome measures rely on subjective 
investigator and patient ratings.  Subjective ratings are not 
always sensitive to detecting small improvements, are subject to 
inter- and intra-rater variability and limited in their ability to 
record detailed or subtle aspects of movement and mobility.  For 
these reasons, objective measurements may provide greater 
sensitivity to detect treatment-related changes where they exist. 
In this review paper, we explore the use of the Kinect 
platform to develop low-cost approaches to objectively measure 
aspects of movement.  We consider published applications that 
measure aspects of gait and balance, upper extremity movement, 
chest wall motion and facial analysis.  In each case, we explore 
the utility of the approach for clinical trials, and the precision 
and accuracy of estimates derived from the Kinect output. 
We conclude that the use of games platforms such as 
Microsoft Kinect to measure clinical outcomes offer a versatile, 
easy to use and low-cost approach that may add significant value 
and utility to clinical drug development, in particular in 
replacing conventional subjective measures and providing richer 
information about movement than previously possible in large 
scale clinical trials, especially in the measurement of gross spatial 
movements.  Regulatory acceptance of clinical outcomes collected 
in this way will be subject to comprehensive assessment of 
validity and clinical relevance, and this will require good quality 
peer-reviewed publications of scientific evidence.  
Keywords—Microsoft Kinect; Motion Capture; Clinician 
Reported Outcomes (ClinRO); Performance Outcomes (PerfO); 
Clinical Trials. 
I.  INTRODUCTION 
Over the past two decades, clinical drug development 
programs have become increasingly complex, involved more 
clinical trials with higher numbers of patients, each including a 
greater volume and variety of assessments and clinical 
procedures and operating with a larger global footprint.  This 
has been associated with spiraling costs.  Developing a new 
drug can take around 12 years from patent application at a cost 
of $1.4 billion in direct costs ($2.6 billion capitalized costs) [1].   
Clinical trials rely upon robust and validated methodologies 
to measure health status and to detect treatment-related changes 
over time to enable the efficacy and safety of new drug 
treatments to be assessed and measured.  In many therapeutic 
areas, the outcomes measures used rely on subjective ratings by 
the investigators at each study research site.  Subjective ratings 
may include measures of symptoms through direct observation 
of the patient, for example depression rating using the 
Hamilton Depression Rating Scale [2], or aspects of 
Parkinson’s Disease symptoms using the Unified Parkinson's 
Disease Rating Scale (UPDRS) [3]; or subjective assessment of 
performance, balance, movement or mobility based on 
observation of the patient conducting a specified movement or 
activity.  Examples include the Fugl-Meyer Assessment (FMA) 
which measures aspects of arm, hand and shoulder movement 
on 3-point verbal response scales [4], the Tinetti Balance 
Assessment measuring aspects of balance and walking 
movement on 2- and 3-point verbal response scales [5], the 
Berg Functional Balance Scale measuring aspects of balance 
and movement on 5-point verbal response scales [6], the 
Dynamic Gait Index measuring aspects of gait during a simple 
walking test on 4-point verbal response scales [7], and many 
others.  Subjective ratings, such as the assessment of a patient 
using a verbal response or numeric rating scales, are not always 
sensitive to detecting small improvements.  Different raters 
may vary in their interpretation of the scale requirements which 
may add variability into the outcomes measured (inter-rater 
variability).  In addition, subjective scales may be prone to 
conscious or unconscious bias, especially when changes over 
time are expected or treatment is unblinded through an open 
design or revealed though the pharmacologic profile of the 
treatment (see [8] for example).   It is sometimes difficult to 
implement measurements that are sensitive enough to detect 
treatment-related changes and able to conclusively show 
treatment effects when they exist.  In addition, using 
investigator observation it is less likely that detailed or subtle 
aspects of movement and mobility can be recorded.  For these 
reasons, accurate objective measurements, where possible, are 
preferred over subjective assessments.  
P.B. and L.F.S. acknowledge the support of the UK NIHR Invention for 
Innovation Programme (Face to Face project).  
2016 International Conference on Interactive Technologies and Games
978-1-5090-3738-4/16 $31.00 © 2016 IEEE
DOI 10.1109/iTAG.2016.17
61
Some solutions already exist that measure aspects of 
movement objectively and enable greater detail to be captured 
and explored.  GAITRite™ (CIR systems Inc., Franklin, NJ, 
USA), for example, uses a walking circuit of pressure pads to 
learn more about gait and balance.  While effective, this 
solution is relatively expensive which may limit its use in large 
scale clinical studies.  In addition, a further solution would be 
required to look at other aspects of movement such as upper 
body and limb movements. 
In this paper, we review the utility of different motion-
based gaming platforms and depth cameras to enable low-cost 
approaches to objectively measure aspects of movement for 
patients in clinical trials.  We consider published applications 
developed using the Microsoft Kinect® (Microsoft Corp., 
Redmond, Washington, USA) platform to measure: (i) aspects 
of gait and balance, with specific reference to stroke, multiple 
sclerosis and Parkinson’s disease; (ii) upper extremity 
movement, with reference to stroke, multiple sclerosis and 
adhesive capsulitis; (iii) chest wall motion analysis for 
respiratory conditions; and (iv) facial analysis for facial 
paralysis in stoke and Bell’s Palsy.  In each case, we explore 
the utility of the approach for clinical trials, in particular 
considering the practical aspects of test conduct, the clinical 
relevance of outcomes measured, and the precision and 
accuracy of estimates derived from the Kinect output. 
II. MOTION-CAPTURE PLATFORMS FOR USE IN 
HEALTHCARE APPLICATIONS 
There is a growing body of applications utilizing motion 
capture technology to study or encourage movement in 
wellness, healthcare and clinical research.  Much of this work 
has been accomplished in the area of rehabilitation to provide 
an engaging environment through which to conduct a regular 
exercise regimen to enable patient feedback and correction to 
ensure that exercises are being performed correctly for optimal 
benefit, and to enable remote assessment and adjustment of 
exercise regimens between clinic visits.  While wearable 
technologies such as accelerometers and gyroscopes, and other 
“non-seeing” sensor systems such as pressure pads (e.g. 
GAITRite) provide useful instrumentation and analysis of 
specific performance tests, motion capture systems offer the 
potential to study a comprehensive digital representation of 
movement, potentially providing a richness of information 
beyond the capability of other systems. 
We focus our review on the use of these optoelectronics 
systems, systems that are able to spatially track movement.  
These systems typically use a variety of methods including 
using detectable markers attached to the body at key joints that 
the optical system can track, and using cameras detecting 
shapes, contrast or depth to interpret position and motion [9]. 
In this section, we review the technical capabilities of the 
Microsoft Kinect gaming platform, the Intel® RealSense™ 
(Intel Corp., Santa Clara, CA, USA) camera range, and Leap 
Motion (Leap Motion Inc., San Francisco, CA, USA), 
CREATIVE® SENZ3D (Creative Technology Ltd., Jurong 
East, Singapore) and Xtion Pro Live (ASUSTek Computer 
Inc., Taipei, Taiwan) solutions with regard to development of 
healthcare applications.  We focus on these as inexpensive 
hardware solutions supported by versatile Software 
Development Kits (SDKs).  These potentially enable 
development of health measurement solutions that could be 
practical for implementation in large scale multicenter clinical 
trials across a variety of clinical settings and not confined to 
movement labs. 
A. Microsoft Kinect 
The Kinect sensor was originally developed for the Xbox 
video game console to provide immersive motion-based 
gaming experiences, and comprises an RGB camera, a depth 
sensor and a multi-array microphone.  The depth sensor 
enables additional information such as the distance of surfaces 
of a 3D object to be determined.  The associated SDK contains 
skeletal tracking and facial analysis components, and these 
enable the position and orientation of body joints and facial 
expression to be determined.  The Microsoft Kinect is available 
in two versions, 1.0 and 2.0.  A comparison of the technical 
specifications of both Kinects can be found in Table I. 
TABLE I.  COMPARISON OF KINECT 1.0 AND 2.0 HARDWARE 
CAPABILITIES 
Capability 
Kinect model 
Kinect 1.0 Kinect 2.0 
RGB Camera (Pixel) 1280×1024 or 640×480 1920×1080 
Depth Camera (Pixel) 640×480 512×424 
Sampling Rate (FPS / Hz) 30 30 
Skeletal Joint Definition 
Points 20 26 
Full Skeleton Tracking 2 6 
Depth Range (m) 30 FPS 30 FPS 
Horizontal Field Of Vision 
(Degrees) 57 70 
Vertical Field Of Vision 
(Degrees) 43 60 
Tilt Motor Yes No 
Audio Stream 4-Mic-Array 4-Mic-Array 
SDK 1.7 Compatibility Yes No 
SDK 1.8 Compatibility Yes No 
SDK 2.0 Compatibility No Yes 
Connectivity (USB) 2.0 or 3.0 3.0 
Approx. price (USD) a 45 190 
a. Prices as of May 2016 
The Microsoft Kinects are low-cost camera systems which 
capture real time depth measurements through triangulation 
alongside RGB and IR imaging. Pagliari and Pinto [10] discuss 
that one of the key drawbacks of the Kinect 1.0 sensor is the 
low geometric quality of the delivered data, noise and low 
repeatability. They also identify that the RGB camera is of poor 
quality in comparison to a standard webcam. Additionally the 
depth data registered by the Kinect 1.0 is of poor quality due to 
the structured light approach not always being robust enough to 
provide a high level of completeness of a framed scene [10]. 
When comparing the two Kinect platforms there is a significant 
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increase in performance quality, yet the same number of 
sensors are used in the construction of the device.  The 
improved resolution and field of vision of the Kinect 2.0 may 
be important in improving accuracy and increasing the 
utilizable area that can be used for performance test 
measurements in patients.   
The Microsoft Kinects do have their limitations with 
regards to the capture speeds which may be realized in the 
measurement of quick and sharp movements.  This is due 
primarily to the modest sampling rate of 30 frames per second 
(30 Hz). Some authors have suggested that this can be 
overcome to a certain degree using spline interpolation 
algorithms which can resample collected data to increase the 
accuracy. For example, Clark et al [11] use this approach to 
reprocess Kinect data to estimate a 100 Hz sampling rate.  
There are a number of alternative hardware solutions which 
have higher capture rates to enable the measurement of quicker 
movements, but these are typically found in machine vision 
systems and motion capture devices which are associated with 
a significantly greater price which may limit their large-scale 
application in clinical trials. The novelty of the Microsoft 
Kinect sensors is that they provide a low-cost solution for the 
real time measurement of image data which allows the tracking 
body and facial movements for analysis and manipulation. 
TABLE II.  COMPARSION OF KINECT 1.0 AND KINECT 2.0 FUNCTIONS 
Function 
Kinect model 
Kinect 1.0 Kinect 2.0 
Face Tracking Yes Yes 
Expression Recognition No (Possible with Additional Algorithms) Yes 
Bone Orientations No Yes 
Body Joint Forces No Yes 
Hand Tracking No (Possible with Additional Algorithms) Yes 
Muscle Simulation No Yes 
Heart Rate Measurement No Yes 
 
As shown in Table II, the Kinect 2.0 can perform a number 
of tasks that the Kinect 1.0 cannot and this is due to the SDK’s 
utilized and how the sensor measures and captures the 
information scanned. Pagliari and Pinto [10] highlight that the 
depth measurement system utilized in the Kinect 2.0 utilizes a 
new measurement principle in order to perform more precise 
skeleton tracking and gesture recognition. 
B. Intel® RealSense™ SR300 
The Microsoft Kinect platforms are the most commonly 
used low-cost gaming camera systems currently utilized to 
develop a wide variety of applications, especially within the 
health care arena. However, there are a number of other 3D 
camera alternatives which offer similar or improved 
functionality dependent on the uses. One alternative is the 
Intel® RealSense™ SR300 which provides users the 
opportunity to work with dynamic background segmentation, 
3D scanning, facial recognition and hand gesture recognition. 
A comparison of the RealSense™ SR300 and Kinect 2.0 can 
be found in Table III. 
TABLE III.  COMPARISON OF INTEL REALSENSE SR300 AND KINECT 2.0 
Capability/Function 
Model 
Intel RealSense SR300 Kinect 2.0 
RGB Camera (Pixel) 1080p at 30 FPS, 720p at 60 FPS 
1920×1080 at 
30 FPS 
Depth Camera (Pixel) 
Up to 640 x 480 at 60 
FPS (Fast VGA, 
VGA), HVGA at 110 
FPS 
512×424 at 
30 FPS 
Skeletal Joint Definition 
Points 22 26 
Face Tracking and 
Recognition Yes Yes 
Expression Recognition Yes Yes 
Gesture Recognition Yes Yes 
Hand Tracking Yes Yes 
Audio Stream Dual Array Microphones 4-Mic-Array 
Connectivity (USB) 3.0 3.0 
Approx. price (USD) b 130 190 
b. Prices as of May 2016 
The Intel camera offers greater resolution and sampling rate 
in comparison to Kinect 2.0, which may offer advantages when 
tracking fine or fast movements.  One of the novelties of the 
RealSense 3D camera range is its versatility for integration into 
a variety of platforms, yet at the same time it remains 
affordable.  Intel have developed a number of camera systems 
which can be integrated into a variety of platforms including 
PCs, external camera systems, smartphone and tablet kits and a 
robotics development kit which gives makers an interface 
board to control cross-platform and open source systems. 
C. Leap Motion 
Leap Motion is a user controlled hand gesture control 
device which is constructed of two monochromatic IR cameras 
and three infrared LEDs. Leap Motion tracks infrared light 
with a wavelength of 850 nanometers and with sub-millimeter 
levels of control, providing a user with an accurate gesture and 
position tracking system (Table IV). Leap Motion is a novel 
touch-free sensor which is used in realistic stereo 3D 
interaction systems where direct selection of stereoscopically-
displayed objects is possible [12]. Hondori and Khademi [9] 
indicate that Leap Motion can detect and track both fingers and 
tools (such as pen) providing  developers with hand and digit 
information such as fingertip position, hand velocity, and 
hand/finger direction. 
D. CREATIVE® SENZ3D 
CREATIVE® SENZ3D is an interactive depth and gesture 
control camera which detects hand gestures and head 
movement through a 720p HD webcam and dual-array 
microphone. The SENZ3D camera is used alongside 
FastAccess 3D facial recognition software which allows the 
user to capture face tracking data to such a degree of detail that 
facial contours can be captured [13].  Combining movement 
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and gesture, facial recognition and voice interaction the 
SENZ3D camera provides an interactive gaming platform 
which has utility in medicine including rehabilitation systems. 
However, the limitation of operating only a single camera or 
voice enabled application at a time reduces its scope of use. A 
full technical specification of the SENZ3D camera can be 
found in Table IV. Although now discontinued, the SENZ3D 
provided developers a low-cost solution to create motion-
sensing applications and games. The replacement CREATIVE® 
LIVE! CAM CONNECT HD retains similar smart face 
tracking capabilities. 
TABLE IV.  COMPARISON OF LEAP MOTION, CREATIVE SENZ3D AND 
XTION PRO LIVE 
Capability/ Function 
Model 
Leap 
Motion SENZ3D Pro Live 
RGB Camera (Pixel) N/A 1280×720 1280×1024 (SGXA) 
Depth Camera (Pixel) N/A 320×240 QVGA 
640 × 480 
VGA at 
30 FPS, 
320 × 240 
QVGA at 60 
FPS 
Sampling Rate/Frame 
Rate (FPS) 30 30 30/60 
Depth Sensing Range 0.025 to 0.6m 0.15 to 1m 0.8 to 3.5m 
Face Tracking and 
Recognition No Yes No 
Expression 
Recognition No No No 
Body Tracking No No Yes 
Hand Tracking Yes Yes Yes 
Gesture Control Yes Yes Yes 
Connectivity (USB) 2.0 or 3.0 2.0 or 3.0 2.0 or 3.0 
Approx. price (USD) c 62 Discontinued Discontinued 
c. Prices as of May 2016 
E. Xtion Pro Live 
Xtion uses an infrared sensor and adaptive depth detection 
utilizing the OpenNI NITE development middleware SDK to 
track precise body movements therefore providing a platform 
which can detect and track the whole body including detailed 
tracking of hands and gestures [9]. This middleware SDK 
allows developers to create motion-sensing applications using 
RGB PC motion sensing software (Table IV).  This solution 
has since been discontinued. 
In conclusion, the use of 3D camera systems and sensors 
has great potential to enable inventive application across a wide 
range of industries, especially within health care and clinical 
research.  Hardware specification improvements may still be 
required when considering accurate tracking of fine or rapid 
movements, and therefore the sampling rates associated with 
the capture of this data may need to improve in future versions. 
However, this has not limited the application of this technology 
in clinical and home health care applications, especially within 
the rehabilitation sector where platforms such as Neuroforma 
(Titanis Sp. z o.o., Warsaw, Poland) [14], JINTRONIX 
(Jintronix, Montreal, Canada) [15], and Face To Face [16] have 
recently been developed; therefore suggesting that 3D cameras 
and sensors will continue to be used in clinical platforms for 
the foreseeable future. 
III. MEASURING OBJECTIVE HEALTH OUTCOMES USING 
MICROSOFT KINECT 
The Kinect platform has been valuable in developing 
interactive solutions for rehabilitation including novel ways of 
engaging patients in regular exercise regimens and solutions to 
ensure that exercises are performed correctly for optimal 
outcomes.  Rehabilitation solutions using Kinect have been 
reported as providing therapeutic benefits in the areas of Stroke 
[17], Parkinson’s Disease [18], Multiple Sclerosis [19] and 
Cerebral Palsy [20], for example.  Through measurement 
within an immersive gaming environment, Kinect has also 
been shown to enable assessments of elements of cognition and 
range of motion [21]. 
The use of games platforms such as Microsoft Kinect to 
measure clinical outcomes offers a versatile, easy to use and 
low cost approach that may add significant value and utility to 
clinical drug development, in particular in replacing 
conventional subjective measures.  Regulatory acceptance of 
clinical trial data will be subject to comprehensive assessment 
of the validity of the data collected in this way, and this will 
require good quality peer-reviewed publications of validation 
evidence.  As seen in the area of rehabilitation, serious gaming 
and motion-based games platforms in particular have the 
potential to enable researchers to understand more, and 
characterize more precisely, the effects of treatment in a wide 
range of disease indications. 
In this section, we review a number of published examples 
of solutions for objective measurement of movement using 
Microsoft Kinect focusing on the areas of gait and balance [11, 
22-23], upper extremity movement [24-26], chest wall motion 
analysis [27] and facial analysis [16] (Table V).  Our aim is not 
to provide a comprehensive review, but to illustrate the 
growing application and potential of the Kinect platform to 
enable objective clinical endpoint assessment. 
A. Gait and Balance 
The ability to track the position of the major body joints is 
useful in tracking gross spatial movements and this information 
can be used to derive descriptive analytics useful in 
summarizing health outcomes.  We review three studies using 
the Kinect depth camera and windows SDK to track 20 body 
joints (Figure 1) to derive gait and balance outcomes measures 
during short performance tests performed by the patient. 
Clinical assessments of gait often rely upon functional 
fitness tests such as timed corridor walking tests or treadmill 
tests for example the six-minute walking test (6MWT); 
pressure pad and balance plate technology; and/or subjective 
tests of aspects of gait such as the Dynamic Gait Index as 
described earlier.  However, all these methods lack the richness 
of information that can be derived by full body motion 
analysis.   
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 Fig. 1.  Body joint skeletal tracking using Microsoft Kinect. 
Clark et al. [11] reported the use of the Kinect platform to 
derive gait parameters in comparison to a standard 10 meter 
walking test.  Their study in 30 stroke patients used a 6 meter 
straight walkway with the Kinect camera placed at the end of 
the route.  Patients were instructed to walk towards the camera 
stopping 0.5 m in front of it, and this enabled the recording of a 
minimum of a full gait cycle (stride) per limb.  The authors 
used spline interpolation to estimate a 100 Hz sampling 
frequency from the 30 Hz data provided by the Microsoft 
Kinect system, which they reported useful in overcoming 
sampling irregularities.  Gait event times for ground contact 
and toe-off were based on the velocity of the ankle joint center.  
These enabled estimation of outcome measures including step 
length and foot swing velocity for the affected and unaffected 
limbs, and anterior displacement of the shoulder center enabled 
mean and peak gait velocity estimation.    Operationally, using 
the Kinect-based assessment system offered advantages to 
other instrumented approaches such as GAITRite, as it required 
minimal setup and minimal interference to the patient – being 
conducted in normal clothes (not requiring shorts or bare feet).  
The authors also concluded that the richness of information 
enabled a broad range of outcomes measures to be derived, 
some of which are not possible with other instrumented 
approaches.  For example, while pressure mat systems can 
provide some spatiotemporal measures of gait such as stride 
length, they cannot provide other potentially important 
measures such as foot swing velocity or variability in trunk 
motion.  Limitations of their approach arose from the field of 
vision of the Kinect camera. 
Accurate assessment of asymmetry and gait variability 
requires the recording of multiple gait cycles, which was not 
possible in a corridor-based test where accurate joint tracking 
requires subjects to remain in the field of vision of the depth 
camera.  In addition, there was some suggestion that, due to the 
setup of their test, patients may decelerate as they approach the 
camera before completing a full gait cycle.  Despite this their 
study showed good concordance of Kinect-derived outcome 
measures compared to gold standard approaches, and robust 
test-retest reliability. 
A second study developed a short maximum speed walking 
test to assess gait parameters in patients suffering from multiple 
sclerosis [22].  Patients were requested to walk as fast as they 
could towards a Kinect camera positioned on a pole, starting 
from a point 2 m outside the camera detection region.  It was 
assumed that this distance was sufficient to achieve maximum 
walking speed.  Using only the hip-center joint, the authors 
derived speed, speed deviation, and 3D left/right and up/down 
deviation measures that were able to distinguish between MS 
patients and healthy volunteers.  Importantly, this study 
identified limitations in the Kinect SDK’s in-built error 
detection system (SDK Recognition Quality) which works to 
identify data artefacts affecting the ability to track the position 
of each joint. The authors developed a custom error correction 
technique that was able to significantly improve accuracy in 
their results compared to the Kinect SDK which tended to fail 
to accurately identify data artefacts and in these cases falsely 
report joint detections. 
A study using a battery of functional performance tests in 
Parkinson’s disease patients showed promise in the use of the 
Kinect depth camera in measuring some but not all clinical 
outcomes measures [23].  The tests included quiet standing, 
multidirectional reaching, stepping and walking on the spot, 
and a number of functional test from the UPDRS: hand 
clasping, finger tapping, foot/leg agility, chair rising and hand 
pronation. In comparison to estimates obtained using a Vicon 
3D motion analysis system (Vicon Motion Systems Ltd., 
Oxford, UK), the authors reported that the Kinect system was 
able to accurately measure the timing (ICCs: 0.940-0.999) and 
gross spatial characteristics of clinically relevant movements 
but not provide the same spatial accuracy for smaller 
movements, such as hand clasping (ICC = 0.009) or toe tapping 
(ICC = 0.038). 
B. Upper Extremity Movement 
Two studies examined the use of Microsoft Kinect to make 
objective measurements of shoulder range of motion [24, 25].  
The first, in stroke patients with chronic hemiparesis [24], 
compared Kinect estimates to those obtained using a gold 
standard motion capture tool and the Fugl-Meyer clinician 
reported outcome scale.  The second [25], explored range of 
motion angles measured from shoulder, trunk and arm vectors 
using Kinect to those obtained by manual goniometer readings 
by qualified clinical readers.  Both studies reported strong 
concordance with the comparator methodologies. 
Olesh et al. [24] reported that reliable estimates were 
obtained using Kinect when each movement was repeated three 
times.  While traditional subjective clinician ratings typically 
request only a single repetition of each movement, this may be 
primarily due to practical time constraints.  The use of a low-
cost, portable solution to make objective measures, such as 
Kinect, may enable more accurate measures and time saving 
compared to goniometer measurement.  Lee et al. [25] 
identified that this approach, in addition to providing accurate 
estimates of shoulder abduction, flexion and rotation angles, 
was able to provide clinical differentiation between patients 
suffering from adhesive capsulitis and healthy volunteers. 
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In their study of arm and finger movement exercises in MS 
patients, Kontschieder et al. [26] used a random forest machine 
learning approach to develop algorithms for analyzing four arm 
and finger movement tests: finger to nose, finger to finger, 
drawing squares and Truncal Ataxia assessment in which both 
arms were held outstretched for 5 seconds.  These were 
developed using a large (training and analysis) dataset of 1,041 
depth videos from MS patients and healthy volunteers.  From 
this work, they concluded the potential of this approach for 
depth-camera supported clinical assessments for a range of 
conditions. 
C. Chest Wall Motion Analysis 
 
Fig. 2.  Chest wall visualisation and change in volume analysis using 
Microsoft Kinectd 
d. Reproduced from Harte et al. [27] without modification under Creative Commons Attribution 4.0 
International License (http://creativecommons.org/licenses/by/4.0/). 
 
One study [27] investigated the use of a prototype system 
using four Kinect sensors positioned perpendicularly, each 1 m 
from the patient, to create a 3D temporal representation of a 
patient’s torso. Results from the prototype were compared to 
spirometry in healthy volunteers and cystic fibrosis patients.  
Using multiple cameras enabled the estimation of volumes 
(Figure 2), as opposed to solely surface changes as provided by 
single camera approaches, important in estimation of 
respiratory outcomes measures.  Spirometry and Kinect data 
were collected during a short performance test requiring the 
subject to perform quiet breathing for 20 s, followed by a 
relaxed vital capacity manoeuver (maximum inspiration and 
expiration) and followed by 20 s of quiet breathing, and was 
repeated three times.  The authors concluded good validity of 
their approach compared to spirometry based on correlations (r 
> 0.8656) and that their system could accurately assess chest 
wall motion even in moving subjects.  This may make this 
approach particularly valuable in assessing the effects of 
pharmacological and physical therapy treatment. 
D. Facial Analysis 
While the facial analysis capabilities of Kinect have been 
used successfully in delivering rehabilitation exercise regimens 
and feedback (see [16] for example), its use to translate digital 
tracking data into health outcome measures that can track 
treatment effects has been less well studied.  However, the 
potential to achieve this is well demonstrated by these 
approaches.  For example, the Face to Face solution [16] 
(Figure 3), funded by the UK NIHR Invention for Innovation 
Programme, is a rehabilitation system for facial paralysis in 
stroke patients.  It recognizes facial expressions by tracking 
movement across the face and applying the recognized motion 
onto an onscreen representation of the user. How the user 
performs a series of facial exercises is assessed by the system 
and scored according to how well the user can undertake each 
of the defined set of expressions. This will enable shorter 
consultations through the presentation of quantified 
improvement, in addition to optimizing the performance of the 
exercises.  Numeric measures of facial expression and 
symmetry enable the tracking of temporal improvements 
arising from pharmacological or physical therapy treatment.   
 
Fig. 3.  Face to Face system for at-home rehabilitation 
The ability of Kinect to identify eye opening and closure 
events may also facilitate measurement of blink rate.  Blink 
rates are believed to reflect the activity of the central 
dopaminergic systems [28].  Patients with Huntingdon’s 
Disease or Schizophrenia show higher blink rates than normal 
subjects; and patients with Parkinson’s disease and progressive 
supranuclear palsy lower blink rates [29].  As an average blink 
takes 300-400 ms to complete, theoretically the ability to 
capture this event should be possible within the sampling 
frequency of the Kinect camera (30 frames per second), 
although more frequent sampling capabilities, such as that of 
the Intel RealSense SR300, may provide more robust measures.   
Facioscapulohumeral muscular dystrophy may present as a 
weakness of the facial muscles.  For example, a patient’s eyes 
may remain slightly open when asleep, or they may be unable 
to tightly close their eyes.  Patients may also experience 
difficulty pursing their lips.  Using the tracking points around 
the mouth and lips it may be possible to instrument a lip 
pursing test, along with other tests of facial muscle strength, 
which could provide valuable outcome measures in these and 
other patient groups.   
Patients with Huntingdon’s Disease are often assessed 
using the UHDRS [30], a component of which considers 
measurement of aspects of motor impersistence, specifically 
difficulty keeping the tongue fully protruded upon command. 
The scale’s tongue protrusion task is performed by asking the 
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patient to hold the tongue extended for 10 seconds and rating 
the response on a 5-point verbal response scale.  Facial tracking 
approaches may enable instrumentation of tests such as these, 
with increased precision of measurement and greater richness 
of information collected. 
IV. DISCUSSION 
Microsoft Kinect provides a low-cost approach to the 
tracking and measurement of movement in clinic and remote 
settings.  The versatile capabilities of the camera and its SDK, 
combined with its low cost and ability to operate on the 
relatively ubiquitous Windows platform provides the potential 
for high utility in clinical trials.  In particular, it may offer 
value in trials that currently rely upon subjective assessments 
of movement.  Software developed using Kinect provides the 
potential to inexpensively distribute solutions to multiple sites 
with less requirement on specialist centers, meaning that 
movement information can be gathered from larger and more 
diverse patient populations and care settings. 
Certain tests, however, may be more suited to the use of 
this approach.  Potential limiting factors include the sampling 
rate of the camera, the resolution and the depth/field of vision.  
Sampling rate and resolution may affect the ability to measure 
spatial accuracy for finer movements such as toe tapping and 
for more rapid movements such as certain gait parameters in 
maximal speed walking tests.  Addressing this concern, some 
researchers have used interpolation methods to approximate 
more frequent sampling rates and this has shown to improve 
accuracy in the assessment of fast movements.  
Increasing the sampling rate of the camera would be a 
valuable addition in future commercial releases, although other 
similarly priced hardware is available that offers this, such as 
the Intel RealSense SR300.  Tests that can be easily conducted 
in a confined area, such as range of motion tests, or those 
requiring less rapid movement over a relatively short distance 
such as one or two gait cycles, are less likely to be affected by 
sampling rate or resolution limitations.  However, the literature 
we have reviewed reports some successful outcomes even in 
the measurement of more challenging movement tasks.    
In general, performance tests that researchers’ seek to 
instrument using Kinect, should be practically conducted in a 
small area within the depth (0.5 to 4.5 m) and field of vision of 
the sensor.  To overcome depth and field of vision limitations, 
some researchers have experimented with the use of Kinect to 
measure gait parameters whilst patients are using a treadmill.  
Xu et al. [31], for example, identified that Kinect could 
accurately estimate heel strike but less accurately estimate toe-
off events in subjects walking at various speeds on a treadmill 
in comparison to the Optotrak Certus motion tracking system 
(Northern Digital Inc., Ontario, Canada).  In addition, Auvinet 
et al. [32] showed that increased accuracy of gait parameters 
could be achieved during treadmill tests by considering the 
extreme values of the distance between knee joints along the 
walking longitudinal axis to increase precision of estimated 
heel strike. 
The ability of Kinect to accurately track joints can be 
affected by having other objects in the field of view.  For 
example, a nearby chair leg could be confused with a patient’s 
leg, although this may be greatly improved with later SDK 
versions which enable seated and standing modes to be 
differentiated.  The distraction of joint tracking capabilities 
when use of walking supports and devices may be a 
consideration, however, in some patient groups.   
While the development of appropriate and pertinent 
performance tests that can be fully measured using Kinect is 
one important area of continued research, for clinical trials 
acceptance it will also be important to be able to present robust 
validation evidence.  Typically this will comprise a number of 
elements: 
 Demonstration that the measurement device (Kinect) is 
providing measurements to an appropriate degree of 
accuracy and precision – for example understanding the 
accuracy of joint position measurement. 
 Demonstration that any special characteristics of a 
particular population do not adversely impact the ability 
to make accurate and precise measurements.  For 
example, if assessing gait parameters ensuring that 
walking with a stick does not affect the accuracy of 
measures, or patients with a more shuffling gait – as 
seen in some Parkinson’s patients for example – does 
not affect the ability to make reliable measurements. 
 Demonstrating the clinical relevance of health outcome 
measures derived from measurement data.  For 
example, new endpoints may be derived with the greater 
information that motion tracking can provide and it will 
be important to show that these have clinical meaning if 
they are to be used in clinical trial regulatory 
submissions.  
This latter element may include comparison of the clinical 
outcomes measured using Kinect to alternative and gold 
standard approaches.  However, it should be noted that in some 
circumstances expecting to demonstrate equivalence to an 
existing clinical trial gold standard approach may not be 
appropriate.  For example, comparing an objective measure to 
a subjective assessment may in fact fail to show equivalence 
due to the limitations of the subjective assessment as opposed 
to a failing in the new measure. 
V. SUMMARY 
Microsoft Kinect is a low-cost depth sensor operating on 
the Windows platform that enables developers to create 
engaging healthcare applications that may be used in clinic or 
in other settings to measure objectively the effects of treatment 
in relation to motion and mobility outcomes.  It has already 
been used extensively in the area of serious games for 
rehabilitation.  This paper has reviewed the technical 
capabilities of the platform, in addition to the Intel RealSense 
SR300, Leap Motion, CREATIVE® SENZ3D and Xtion Pro 
Live cameras in relation to tracking a variety of aspects of 
movement and motion.  We have further reviewed a number of 
studies using Microsoft Kinect to enable objective assessment 
of aspects of motion and mobility that may be of value in 
clinical trials.  These examples have shown that Kinect can 
provide clinical outcome measures to a high degree of 
precision and accuracy, particularly those relating to gross 
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spatial movements.  Particular value may be seen in the ability 
to replace certain clinician subjective assessments with 
accurate and sensitive objective outcome measures, and to 
provide richer information with which to understand treatment 
effects. 
While more research will be required to ensure that Kinect-
based derived health outcomes measures have robust validity 
and clinical relevance, their potential to enhancing the 
experience of participating in a clinical trial, and as a means of 
collecting novel endpoint data is evidenced by the examples 
reviewed in this paper. 
While highly regulated, the pharmaceutical industry 
remains actively interested in applying innovative approaches 
that improve the operation of clinical trials and the thorough 
understanding of treatment effects.  Leveraging video gaming 
platforms such as Microsoft Kinect remain an industry interest 
area where more exploration, development and examples of 
successful application are needed to drive their potential 
adoption in clinical trials. 
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